Inhaled NO inhibits platelet aggregation and elevates plasma but not intraplatelet cGMP in healthy human volunteers

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 285, Issue 2 54-2, 2003, Pages

  Beghetti, Maurice ^a   Sparling, Catherine ^a   Cox, Peter N ^a   Stephens, Derek ^a   Adatia, Ian ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

cGMP; Nitric oxide; Platelet aggregation

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; COLLAGEN; CYCLIC GMP; NITRIC OXIDE; RISTOCETIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HOMEOSTASIS; HUMAN; INHALATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; TIME SERIES ANALYSIS; VELOCITY;

EID: 0038299375     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00622.2002     Document Type: Article

References (33)

1. Adatia I, Perry S, Moore P, Landzberg M, and Wessel DL. Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantation. J Am Coll Cardiol 25: 1652-1664, 1995.
2. Adrie C, Bloch KD, Moreno PR, Hurford WE, Guerrero JL, Holt R, Zapol WM, Gold HK, and Semigran MJ. Inhaled nitric oxide increases coronary artery patency after thrombolysis. Circulation 94: 1919-1926, 1996.
3. Albert J, Norman M, Wallén NH, Frostell C, and Hjemdahl P. Inhaled nitric oxide does not influence bleeding time or platelet function in healthy volunteers. Eur J Clin Invest 29: 953-959, 1999.
4. Albert J, Wallén NH, Bröijersén A, Frostell C, and Hjemdahl P. Effects of inhaled nitric oxide compared with aspirin on platelet function in vivo in healthy subjects. Clin Sci (Lond) 91: 225-231, 1996.
5. Albert J, Wallén NH, Li N, Frostell C, and Hjemdahl P. Neither endogenous nor inhaled nitric oxide influences the function of circulating platelets in healthy volunteers. Clin Sci (Lond) 97: 345-353, 1999.
6. ++ concentrations. Thromb Res 75: 232-242, 1994.
7. Christou H, Magnani B, Morse DS, Allred EN, Marter LJV, Wessel DL, and Kourembanas S. Inhaled nitric oxide does not affect adenosine 5′-diphosphate-dependent platelet activation in infants with persistent pulmonary hypertension of the newborn. Pediatrics 102: 1390-1393, 1998.
8. Davidson D, Barefield ES, Kattwinkel J, Dudell G, Damask M, Straube R, Rhines J, and Chang CT. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicentre study. Pediatrics 101: 325-334, 1998.
9. Finer NN, Sun JW, Rich W, Knodel E, and Barrington KJ. Randomized, prospective study of low-dose versus high-dose inhaled nitric oxide in the neonate with hypoxic respiratory failure. Pediatrics 108: 949-955, 2001.
10. George TN, Johnson KJ, Bates JN, and Segar JL. The effect of inhaled nitric oxide therapy on bleeding time and platelet aggregation in neonates. J Pediatr 132: 731-734, 1998.
11. Gordge MP, Hothersall JS, and Noronha-Dutra AA. Evidence for a cyclic GMP-independent mechanism in the antiplatelet action of S-nitroglutathione. Br J Pharmacol 124: 141-148, 1998.
12. Gothberg S and Edberg KE. Inhaled nitric oxide to newborns and infants after congenital heart surgery on cardiopulmonary bypass. A dose response study. Scand Cardiovasc J 34: 154-158, 2000.
13. Gries A, Bode C, Peter K, Herr A, Böhrer H, Motsch J, and Martin E. Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo. Circulation 97: 1481-1487, 1998.
14. Gries A, Herr A, Motsch J, Holzmann A, Weimann J, Taut F, Erbe N, Bode C, and Martin E. Randomized, placebo-controlled, blinded and cross-matched study on the antiplatelet effect of inhaled nitric oxide in healthy volunteers. Thromb Haemost 83: 309-315, 2000.
15. Högman M, Frostell C, Arnberg H, and Hedenstierna G. Bleeding time prolongation and NO inhalation. Lancet 341: 1664-1665, 1993.
16. Kermarrec N, Zunic P, Beloucif S, Benessiano J, Drouet L, and Payen D. Impact of inhaled nitric oxide on platelet aggregation and fibrinolysis with endotoxic lung injury role of cyclic guanosine 5′-monophosphate. Am J Respir Crit Care Med 158: 833-839, 1998.
17. Malmros C, Blomquist S, Dahm P, Mårtensson L, and Thörne J. Nitric oxide inhalation decreases pulmonary platelet and neutrophil sequestration during extracorporeal circulation in the pig. Crit Care Med 24: 845-849, 1996.
18. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, and Kadowitz PJ. Evidence for the inhibitory role of guanosine 3′5′ monophosphate in ADP induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 57: 946-955, 1981.
19. Moncada S and Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 329: 2002-2012, 1993.
20. a. Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in term and near-term infants: neurodevelopmental follow-up of the neonatal inhaled nitric oxide study group (NINOS). J Pediatr 136: 611-617, 2000.
21. Nguyen BL, Saitoh M, and Ware JA. Interaction of nitric oxide and cGMP with signal transduction in activated platelets. Am J Physiol Heart Circ Physiol 261: H1043-H1052, 1991.
22. 2 formation on close contact of human platelets in media with a low concentration of ionized calcium. Blood 70: 647-651, 1987.
23. Pawloski JR, Swaminathan RV, and Stamler JS. Cell-free and erythrocytic S-nitrosohemoglobin inhibits human platelet aggregation. Circulation 97: 263-267, 1998.
24. Rabinovitch M, Andrew M, Thom H, Trusler GA, Williams WG, Rowe RD, and Olley PM. Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart disease. Circulation 76: 1043-1052, 1987.
25. Radomski MW, Palmer RMJ, and Moncada S. The antiaggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 92: 639-646, 1987.
26. Radomski MW, Palmer RMJ, and Moncada S. Characterization of the L-arginine: nitric oxide pathway in human platelets. Br J Pharmacol 101: 325-328, 1990.
27. Radomski MW, Palmer RMJ, and Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 87: 5193-5197, 1990.
28. Rajah SM, Penny AF, Crow MJ, Pepper MD, and Watson DA. The interaction of varying doses of dipyridamole and acetyl salicylic acid on the inhibition of platelet functions and their effect on bleeding time. Br J Clin Pharmacol 8: 483-489, 1979.
29. Rimar S and Gillis CN. Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation. Circulation 88: 2884-2887, 1993.
30. Samama CM, Diaby M, Fellahi JL, Mdhafar A, Eyraud D, Arock M, Guillosson JJ, Coriat P, and Rouby JJ. Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology 83: 56-65, 1995.
31. 2 synthesis in human blood platelets. FEBS Lett 442: 162-166, 1999.
32. Watanabe H, Kakihana M, Ohtsuka S, Enomoto T, Yasui K, and Sugishita Y. Platelet cyclic GMP a potentially useful indicator to evaluate the effects of nitroglycerin and nitrate intolerance. Circulation 1993: 29-36, 1993.
33. Wessel DL, Adatia I, Giglia TM, Thompson JE, and Kulik TJ. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass. Circulation 88: 2128-2138, 1993.